定期使用质子抑制剂与心血管结果之间的关联:一项大型前性队列研究
Zhi-Hao Li1, Wen-Fang Zhong1, Cheng-Shen Qiu1
1Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China.
International journal of cardiology
|November 7, 2023
概括
定期使用质子抑制剂 (PPI) 与心血管疾病 (CVD) 风险增加有关,包括心脏病发作和中风. 医疗保健提供者在为患者开处方PPI时应考虑这些发现.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 质子抑制剂 (PPI) 通常用于与酸有关的胃肠道疾病.
- 定期使用PPI与心血管疾病 (CVD) 风险之间的潜在联系尚未完全理解.
- 这项研究调查了PPI与大量人口队列中发生的心血管疾病之间的关联.
研究的目的:
- 确定定期使用质子抑制剂 (PPI) 是否与心血管疾病 (CVD) 发病率增加有关.
- 评估PPI与特定心血管疾病组件之间的关联,包括冠心病,中风,心力衰竭,心房动和静脉血栓栓塞.
- 提供关于PPI处方的临床决策的证据.
主要方法:
- 一项前性队列研究利用了来自459,207名英国生物库参与者的数据 (2006-2018).
- 参与者在入学时没有流行心血管疾病,并对发生的心血管疾病事件进行了跟踪.
- 考克斯的比例危险模型被用来计算危险比率 (HRs) 和95%置信区间 (CI),并根据多个混因素进行调整.
主要成果:
- 在随访期间,记录了26,346起心血管疾病事件事件.
- 与非使用者相比,经常使用PPI的患者患心血管疾病的风险明显更高 (HR 1.44,95% CI 1.39-1.50).
- 冠心病 (HR1.65),中风 (HR1.21),心力衰竭 (HR1.61),心房动 (HR1.17) 和静脉血栓塞栓症 (HR1.36) 的风险增加.
结论:
- 定期使用质子抑制剂 (PPI) 与心血管疾病 (CVD) 结果的风险更高有关.
- 这些发现表明,临床医生在开处方PPI时需要谨慎.
- 可能需要进一步的研究来阐明这种关联背后的机制.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
539
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
539
Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
490
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
490
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535


